An update from Transact Technologies ( ($TACT) ) is now available. On March 31, 2026, TransAct Technologies amended its long-standing lease for its......

Pinterest (PINS) told investors it had built a resilient ad machine. Tariffs, macro pressure, retail weakness. None of it, executives said, would k......

Gossamer (GOSS) told investors its Phase 3 PROSERA study was progressing, with executives expressing confidence in the trial’s design and patient s......

Snowflake (SNOW) looked unstoppable. Surging consumption. Confident forecasts. A bold ten billion dollar revenue target. But behind the scenes, eff......

Coty ($COTY) told investors a comeback was already underway. Growth was coming back. Profits were set to rebound. Everything looked on track. But a......

Aldeyra Therapeutics ($ALDX) told investors its dry eye drug reproxalap was showing strong, consistent results across multiple late-stage trials. F......

Driven Brands ($DRVN) told investors the numbers looked solid. But a new lawsuit claims the company’s financial statements were riddled with accoun......

Nektar Therapeutics ($NKTR) told investors its REZOLVE-AA trial followed stated eligibility criteria and protocol standards. Executives repeatedly ......

monday.com ($MNDY) told investors AI innovation, enterprise expansion, and multi-product growth supported a path to $1.8 billion in 2027. But the l......

In a report released on March 31, Christian Faitz from Kepler Capital maintained a Buy rating on AlzChem Group AG, with a price target of €177.00. ......